Covered recipient · General Payments record
JILLIAN M KUHLMANN
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$577.22
- Reported across 34 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $271.16 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $62.06 | 4 |
| Lilly USA, LLC | $53.59 | 3 |
| Novo Nordisk AS | $42.26 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $34.35 | 2 |
| ABBVIE INC. | $30.60 | 2 |
| PFIZER INC. | $17.47 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.16 | 1 |
| Acerta Pharma LLC | $14.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.30 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107491359 | CMS |
| ABBVIE INC. | $14.30 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107491361 | CMS |
| Amgen Inc. | $19.83 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117302531 | CMS |
| Amgen Inc. | $14.54 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117603455 | CMS |
| Amgen Inc. | $13.54 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117603457 | CMS |
| Amgen Inc. | $14.15 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117603459 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.67 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105385993 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.16 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117987636 | CMS |
| Lilly USA, LLC | $19.89 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135722345 | CMS |
| Lilly USA, LLC | $16.05 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135645837 | CMS |
| Lilly USA, LLC | $17.65 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135712570 | CMS |
| Novartis Pharmaceuticals Corporation | $19.43 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086970886 | CMS |
| Novartis Pharmaceuticals Corporation | $14.92 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086970888 | CMS |
| Novo Nordisk Inc | $22.77 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100653455 | CMS |
| Novo Nordisk Inc | $19.49 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100364897 | CMS |
| PFIZER INC. | $17.47 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132117820 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.